Efficacy of favipiravir in COVID-19: A retrospective two center comparative study
The Journal of Infection in Developing Countries · 2024
DOI: 10.3855/jidc.18039 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Elif Tukenmez Tigen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Marmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, Turkey. Hauptthemen laut MEDLINE: Pyrazines, COVID-19 Drug Treatment, Amides, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Favipiravir (FVP) is an antiviral, targeting RNA-dependent RNA polymerase. We aimed to evaluate the efficacy of FVP as a treatment for COVID-19.
Methods
We conducted a retrospective study in two centers (San Martino University Hospital in Genova, Italy, and Marmara University Pendik Training and Research Hospital, Turkey). Adult patients (inpatients) diagnosed with COVID-19 between March and June 2020 were included. All patients in the Italian center received the standard of care (SoC) treatment, while in the Turkish center patients received FVP in addition to SoC.
Results
Six hundred-nineteen patients were analyzed (225 from Turkey, all treated with FVP, and 394 from Italy, none treated with FVP). Propensity score-matching was done in 142 patients (71 from the SoC group vs. 71 from the SoC + FVP group). A Higher requirement of NIV/CPAP (n = 38; 53.5%) was registered in the SoC group compared to the SoC + FVP group (n = 9; 12.7%). A higher frequency of intubation was registered in the SoC + FVP group (n = 25; 35.2% vs n = 13, 18.3%). There was a trend towards better survival in SoC + FVP treated patients with HR = 0.64 (95% CI 0.30-1.34). At 28 days the OS was, respectively, 70.3% (95% CI: 53.2-82.1) vs 80.3% (95% CI: 69.0-87.8).
Conclusions
The addition of FVP to SoC did not show a significant difference in survival and invasive and noninvasive (CPAP/NIMV) mechanical ventilation compared to standard of care in moderate and severe COVID-19-infected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Marmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, Turkey.
- Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genova, Italy.
- University of Genova, Department of Health Sciences- Section of Biostatistics, Genova, Italy.
- University of Health Sciences, Public Health, İstanbul, Turkey.
Zitieren
APA
Tukenmez Tigen, E., Mikulska, M., Erturk Sengel, B., Signori, A., Dettori, S., Tutino, S., Guner, A. E., Odabasi, Z., Korten, V., & Bassetti, M. (2024). Efficacy of favipiravir in COVID-19: A retrospective two center comparative study. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.18039
Vancouver
Tukenmez Tigen E, Mikulska M, Erturk Sengel B, Signori A, Dettori S, Tutino S, et al. Efficacy of favipiravir in COVID-19: A retrospective two center comparative study. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.18039
BibTeX
@article{TukenmezTigen2024,
author = {Tukenmez Tigen, Elif and Mikulska, Malgorzata and Erturk Sengel, Buket and Signori, Alessio and Dettori, Silvia and Tutino, Stefania and Guner, Abdullah Emre and Odabasi, Zekaver and Korten, Volkan and Bassetti, Matteo},
title = {Efficacy of favipiravir in COVID-19: A retrospective two center comparative study},
journal = {The Journal of Infection in Developing Countries},
year = {2024},
doi = {10.3855/jidc.18039}
}
EUVIMED